Evidence map›Paper›PMID 30747050›Full record

ReviewThyroid : official journal of the American Thyroid Association2019

Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.

Tihana Ibrahimpasic, Ronald Ghossein, Jatin P Shah, Ian Ganly

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Thyroid : official journal of the American Thyroid Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04821336 (Cholesterol Metabolites), which is not on this map. Cited by 167 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 7 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04821336 completednot on this mapstarted 2021, after this paper: background citation

Cholesterol Metabolites (Dendrogenin A or DDA, 6-oxo-cholestane-3β,5α-diol or OCDO,...) Quantification in Malignant Versus Normal Human Thyroid Tissue Refractory to Iodine

TypeobservationalSponsorInstitut Claudius RegaudRan2021 to 2022Enrolled30ConditionsThyroid CancerArmsMetabolites dosage
3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 7 syntheses or guidelines pooled it, 242 citations in OpenAlex.

  1. Pooled it
  2. SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.Virchows Archiv : an international journal of pathology · 2024
    Pooled it
  7. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2021
    Guideline
  8. Trial
  9. Enhancing Radioiodine Incorporation inThyroid : official journal of the American Thyroid Association · 2022
    Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Acetate Metabolism in Thyroid Cancer Progression.International journal of molecular sciences · 2026
    Article

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tihana Ibrahimpasic1 Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Ronald Ghossein2 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jatin P Shah1 Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Ian Ganly1 Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE in Thyroid CancerP50CA172012 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FAGIN, JAMES A · 2014 to 2018
$10.3M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA172012
6 · The paper itself

Abstract

backgroundPoorly differentiated thyroid cancer (PDTC) is a rare but clinically highly significant entity because it accounts for most fatalities from non-anaplastic follicular cell-derived thyroid cancer. Due to the relative rarity of the disease and heterogeneous diagnostic criteria, studies on PDTC have been limited. In light of the evolution of ultra-deep next-generation sequencing technologies and through correlation of clinicopathologic and genomic characteristics of PDTC, an improved understanding of the biology of PDTC has been facilitated. Here, the diagnostic criteria, clinicopathologic characteristics, management, and outcomes in PDTC, as well as genomic drivers in PDTC reported in recent next-generation sequencing studies, are reviewed. In addition, future prospects in improving the outcomes in PDTC patients are reviewed. SUMMARY: PDTC patients tend to present with adverse clinicopathologic characteristics: older age, male predominance, advanced locoregional disease, and distant metastases. Surgery with clearance of all gross disease can achieve satisfactory locoregional control. However, the majority of PDTC patients die of distant disease. Five-year disease-specific survival for PDTC patients has been reported at 66%. On multivariate analysis, reported predictors of poor survival in PDTC patients have been older age (>45 years), T4a pathological stage, extrathyroidal extension, high mitotic rate, tumor necrosis, and distant metastasis at presentation. BRAF

conclusionsThese new insights into the clinicopathologic and molecular characteristics of PDTC, together with further advancement in ultra-deep sequencing technologies, will be conducive in narrowing the focus in order to develop novel targeted therapies and improve the outcomes in PDTC patients.

Indexed as

AgedCell DifferentiationDisease-Free SurvivalFemaleGenomicsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationNeoplasm MetastasisPromoter Regions, Geneticras ProteinsThyroid Cancer, PapillaryThyroid Carcinoma, AnaplasticThyroid Neoplasmsras Proteinsnext-generation sequencingoutcomespoorly differentiatedpresentationthyroid cancer

Identifiers

PMID30747050
PMCPMC6437626
OpenAlexW2914407722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.